We are live on ! Find out more
ARRY

Array Biopharma Inc
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

Back to rankings

1 hedge funds and large institutions have $110K invested in Array Biopharma Inc in 2025 Q2 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 1 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1 → 1 (0)

33% less capital invested

Capital invested by funds: $165K → $110K (-$54.6K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
CWM
CIBC World Markets
New York
-$89.5K

ARRY Hedge Fund Activity: Q2 2025 in Review

1 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q2 2025, worth a combined $110K — down 33% from $165K a quarter earlier.

Fund positioning in ARRY was balanced in Q2 2025: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.

The largest seller was CIBC World Markets, cutting an estimated $89.5K.

  • 1 institutional investor held Array Biopharma Inc (ARRY) as of Q2 2025, unchanged from Q1 2025.
  • Funds reported $110K of Array Biopharma Inc stock for Q2 2025, down 33% quarter-over-quarter.
  • 0 funds opened new Array Biopharma Inc positions in Q2 2025 and 0 closed out.
  • The largest Array Biopharma Inc seller in Q2 2025 was CIBC World Markets, an estimated $89.5K sold.

Based on aggregated 13F filings for Q2 2025.